An open-label study evaluating the effectiveness of aripiprazole for schizophrenia patients with dopamine supersensitivity psychosis.
- Conditions
- Schizophrenia, Schizaffective disorder
- Registration Number
- JPRN-UMIN000012574
- Lead Sponsor
- Department of Psychiatry, Chiba University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Not provided
1)Under treatment with clozapine 2)A treatment history of ECT in the 3 months prior to the study enrollment 3)In a coma state 4)Under profound effects by CNS inhibition drugs such as barbiturates or anesthetic agent 5)Under treatment with adrenergic agent 6)Hypersensitivity to any content in the trial drug 7)Lacking notification of diagnosis 8)Presence of any other Axis 1 or 2 psychiatric disorder according to DSM-4-TR 9)Pregnant or suspected of pregnancy 10)Participation history of a clinical trial with any intervention (i.e., except for observational study), within recent 3 months prior to the study enrollment 11)With suicide history within the 1 year proor to the study enrollment 12)Assessment as unsuitable for participation in the study by the study physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive and Negative Syndrome Scale(PANSS: Kay et al., 1981)
- Secondary Outcome Measures
Name Time Method Global Assessment of Functioning (GAF) Clinical Global Impression Scale-Severity/-Change Extrapyramidal Symptom Rating Scale (ESRS: Chouinard and Margolese, 2005)